These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25806234)

  • 1. Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?
    Massuti B; Sanchez JM; Hernando-Trancho F; Karachaliou N; Rosell R
    Transl Lung Cancer Res; 2013 Jun; 2(3):208-21. PubMed ID: 25806234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How close are we to customizing chemotherapy in early non-small cell lung cancer?
    Ioannidis G; Georgoulias V; Souglakos J
    Ther Adv Med Oncol; 2011 Jul; 3(4):185-205. PubMed ID: 21904580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
    Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
    Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
    J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
    Han Y; Wang XB; Xiao N; Liu ZD
    Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
    Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
    Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the mRNA expression of
    Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
    Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.
    Breen D; Barlési F
    Eur J Cardiothorac Surg; 2008 May; 33(5):805-11. PubMed ID: 18342529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?
    Aggarwal C; Somaiah N; Simon GR
    J Natl Compr Canc Netw; 2010 Jul; 8(7):822-32. PubMed ID: 20679541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer.
    He D; Ma X; Wu Z; Wang Y; Zhao S; Han F; Sun W
    Oncol Lett; 2017 Sep; 14(3):3463-3472. PubMed ID: 28927101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
    Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
    Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
    Zou ZQ; Du YY; Sui G; Xu SN
    Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic and targeted therapies for early-stage lung cancer.
    Byron E; Pinder-Schenck M
    Cancer Control; 2014 Jan; 21(1):21-31. PubMed ID: 24357738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.